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E pilepsy is a chronic brain disorder marked by recurrent,  unprovoked epileptic seizures.  It affects 
5-9% of the general population.  Its etiology is heteroge-
neous,  with structural,  genetic,  infectious,  metabolic,  
and immune components [1].  Nevertheless,  patients 
with epilepsy share common symptoms,  i.e.,  epileptic 
seizures,  which are characterized by transient occur-
rence of signs and/or symptoms that result from abnor-
mal excessive or synchronous neuronal activity in the 
brain [2].  It is not known how the various causes of 
epilepsy lead to the common phenomenon of excessive 
neuronal firing.
Epileptic seizures involve alterations in the concen-
tration of ions (e.g.,  sodium,  calcium) and neurotrans-
mitters (e.g.,  glutamic acid,  gamma-aminobutyric acid 
[GABA]),  leading to an imbalance between excitation 
and inhibition in the central nervous system.  Current 
antiepileptic drugs (AEDs) mainly target such mecha-
nisms by suppressing neuronal excitation (e.g.,  volt-
age-gated sodium and calcium channel blocking,  gluta-
mate receptor antagonism) or enhancing neuronal 
inhibition (e.g.,  inhibition of GABA catabolism,  chlo-
ride channel enhancement).
Recently,  lactate dehydrogenase (LDH) has been 
reported to be a potential new target of AEDs,  and 
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stiripentol,  one of the currently available AEDs,  has 
been shown to have an LDH-inhibiting effect [3].  Thus,  
understanding and targeting cellular metabolism may be 
a new approach to controlling epileptic seizures.  Blood 
and urine are not ideal samples for investigating patho-
logical metabolic processes in the brain because the 
blood-brain barrier and the blood-cerebrospinal fluid 
(CSF) barrier isolate the brain from the peripheral sys-
tem.  CSF samples have the disadvantage of invasive 
collection; however,  if available,  metabolic profiling of 
the CSF in patients with epilepsy may help elucidate 
changes in the metabolites in the brain that are associ-
ated with epileptic seizures,  which may in turn provide 
clues for discovering new targets for AEDs.
In this study,  we performed metabolome analysis of 
CSF samples obtained from pediatric patients with and 
without epilepsy using gas chromatography-tandem 
mass spectrometry (GC-MS/MS).  We aimed to dis-
cover differences between the metabolic profiles of epi-
leptic and non-epileptic patients in 2 age groups,  0-5 
(< 6) years of age and 6-17 (≥ 6 and < 18) years of age.  
We also investigated which metabolites were affected by 
AEDs.
Materials and methods
Subjects. This study included 64 patients (34 
patients with epilepsy and 30 patients without epilepsy) 
who were admitted to the Department of Child 
Neurology at Okayama University Hospital and under-
went lumbar puncture to collect CSF samples for inves-
tigation of neurological symptoms from December 
2012 to December 2016 and whose unused CSF samples 
were available.  Patients with known inherited meta-
bolic diseases were excluded,  because their metabolic 
profiles would likely show a high degree of deviation.  
Patients with other comorbidities (e.g.,  intellectual dis-
ability),  underlying causes (e.g.,  focal cortical dyspla-
sia),  and those receiving treatment (e.g.,  AEDs) were 
not excluded.  We chose to include a variety of patients 
to identify candidate metabolites that show common 
changes across diverse etiologies,  and because the num-
ber of patients undergoing lumbar puncture in the clin-
ical setting is limited.  This study was approved by the 
Research Ethics Board at Okayama University Hospital.  
Written informed consent was obtained from the 
patients’ guardians before the procedure.
Sample collection protocol. Lumbar puncture was 
conducted after 4-6 h of fasting.  The CSF samples were 
aliquoted and used for routine laboratory tests (e.g.,  cell 
count,  protein,  glucose) and for analysis of monoamine 
neurotransmitters,  pyridoxal-5’-phosphate,  and 
5-methyltetrahydrofolate,  as needed,  at our laboratory.  
The unused CSF samples were stored at −80°C within 
1 h after collection until metabolome analysis.
Metabolome analysis. The CSF samples were 
prepared according to a previously reported method 
[4].  GC-MS/MS analysis was performed using a 
GC-MS/MS TQ8040 (Shimadzu,  Kyoto,  Japan) system.  
Peak identification was performed automatically and 
then confirmed manually based on the specific precur-
sor and product ions and retention time.  The database 
used in this study includes data on 475 peaks from 333 
metabolites [5].
Statistical analysis. Statistical analyses were per-
formed using R 3.4.2 (https://cran.r-project.org/).  For 
patient group comparison,  Wilcoxon’s test,  Fisher’s 
exact test,  and chi-square test were performed.  
Correlation analysis was performed using Spearman’s 
correlation coefficient.  Metabolic profiles were analyzed 
in two age groups: 0-5 (< 6) years of age (pre-school 
age) and 6-17 (≥ 6 and < 18) years of age (school age),  
because the concentrations of many metabolites are 
known to be age-dependent.  The concentration data of 
all metabolites were logarithmically transformed.  To 
check for outliers,  principal component analysis (PCA) 
was conducted after data scaling to a mean of zero and 
a variance of one.  To investigate the effect of epilepsy 
(vs. non-epilepsy) and AEDs on individual metabolites,  
multiple regression analyses were performed.  Because 
of the many multiple regression analyses for all metab-
olites,  p-values were adjusted by controlling the false 
discovery rate using the R package “qvalue” to calculate 
q-values (http://genomics.princeton.edu/storeylab/
qvalue/).  The significance level was set at 0.05.
Results
Subject characteristics. Subject characteristics 
are presented in Table 1 and Table 2.  There were 34 
patients with epilepsy and 30 patients without epilepsy.  
The age group of 0-5 years consisted of 22 patients with 
epilepsy and 13 patients without epilepsy.  The age 
group of 6-17 years consisted of 12 patients with epi-
lepsy and 17 patients without epilepsy.  There were no 
significant differences in age and sex between the 
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????? ?　 Clinical characteristics of subjects
Case No. Age Sex Antiepileptic drugs Diagnosis
Patients with epilepsy
1  0y  4m M FE,  developmental delay
2  0y  4m M ZNS,  PB West syndrome,  post-herpes simplex encephalitis
3  0y  5m F CBZ Benign infantile epilepsy
4  0y  6m F LEV,  CZP West syndrome,  FCD
5  1y  3m M PHT FE,  developmental delay,  KCNQ2 gene abnormality
6  1y 10m F PHT,  TPM FE,  cavernous angioma
7  1y 11m F VPA GE,  developmental delay
8  2y  1m F VPA GE,  intellectual disability
9  2y  5m F VPA,  ZNS FE,  FCD
10  2y  7m F LEV,  CBZ West syndrome,  intellectual disability
11  2y 10m M GE
12  3y  2m F VPA,  ZNS,  LTG West syndrome,  intellectual disability
13  3y  3m F VPA Epilepsy with myoclonic-atonic seizures
14  3y  4m M VPA,  ESM Lennox-Gastaut syndrome
15  3y  5m M VPA Epileptic encephalopathy with CSWS
16  3y  6m M VPA,  DZP GFE
17  4y  0m M VPA,  LEV,  CBZ,  TPM GFE,  intellectual disability
18  4y  4m M VPA,  LEV GFE,  intellectual disability
19  4y  7m M VPA FE,  intellectual disability
20  4y  7m F VPA,  LEV FE,  intellectual disability
21  5y  3m M ZNS,  CBZ FE,  FCD
22  5y 10m M VPA,  LTG GE,  intellectual disability,  autism
23  6y  6m F ZNS GE,  intellectual disability
24  7y  5m M VPA,  LEV,  ESM,  STM Epileptic encephalopathy with CSWS,  intellectual disability,  autism,  ADHD
25  9y  1m F VPA,  TPM,  ESM,  RFN Lennox-Gastaut syndrome,  intellectual disability,  autism
26  9y  3m M VPA,  LTG FE,  subcortical band heterotopia
27  9y  7m F VPA,  LEV,  TPM,  STM,  CLB FE,  autism
28  9y  8m M ZNS,  CBZ FE,  borderline intelligence
29 10y 11m M CBZ,  CZP FE,  dystonia,  intellectual disability
30 12y 10m F VPA,  LEV FE,  FCD
31 13y  7m M LTG,  PHT,  CLB FE,  intellectual disability
32 14y 10m F LEV,  ZNS,  CZP,  CLB,  PB,  ESM GE,  intellectual disability,  autism
33 14y 10m M ZNS FE
34 15y  4m F LEV,  CBZ FE,  intellectual disability
Patients without epilepsy
35  0y  4m M Hypertonia,  developmental delay
36  0y  6m F Benign neonatal myoclonus
37  0y  9m F Cerebellar hypoplasia
38  1y  1m M Developmental delay
39  1y  1m F Congenital ﬁber-type disproportion myopathy
40  2y  0m M ZNS,  CBZ Suspected tic disorder
41  2y  0m M Intellectual disability
42  2y  1m F Intellectual disability
43  2y  2m F Intellectual disability,  hypotonia
44  2y  6m F Benign congenital hypotonia
45  3y  0m M Autism
46  3y  7m M Intellectual disability
47  5y  6m M VPA,  DZP Autism
48 10y  4m F Equinus foot
49 10y  9m F Suspected restless legs syndrome
50 11y  2m M Intellectual disability,  idiopathic basal ganglia calciﬁcation
51 11y  8m M ADHD,  Tourette syndrome
52 11y  9m F Equinus foot
53 12y  7m F Somatoform disorder
54 12y  8m M Hypersomnia
55 12y  9m M Conversion disorder
56 13y  2m M Paroxysmal kinesigenic dyskinesia
57 13y  2m F Narcolepsy
58 14y  3m F Hypersomnia
59 14y  4m F Hypersomnia
60 14y  8m F Transient muscle weakness
61 15y  1m M Kleine-Levin syndrome
62 15y  6m M Hypersomnia
63 15y  7m M Narcolepsy
64 16y  7m F Myasthenia gravis
ADHD,  attention-deﬁcit hyperactivity disorder; CBZ,  carbamazepine; CLB,  clobazam; CSWS,  continuous spike-waves during sleep; CZP,  clonazepam; DZP,  diazepam; ESM,  etho-
suximide; FCD,  focal cortical dysplasia; FE,  focal epilepsy; GE,  generalized epilepsy; GFE,  combined generalized and focal epilepsy; LEV,  levetiracetam; LTG,  lamotrigine; MDL,  
midazolam; PB,  phenobarbital; PHT,  phenytoin; RFN,  ruﬁnamide; STM,  sulthiame; TPM,  topiramate; VPA,  valproic acid; ZNS,  zonisamide.
patients with epilepsy and those without epilepsy in 
either age group.  The proportions of patients treated 
with AEDs were significantly different,  with patients 
receiving valproic acid (VPA) in both age groups,  and 
patients receiving levetiracetam (LEV),  zonisamide 
(ZNS),  and benzodiazepines (BZDs) in the age group of 
6-17 years.  These AEDs were incorporated as indepen-
dent variables for subsequent multiple regression analy-
sis.  Regarding routine laboratory tests,  the concentra-
tions of CSF protein,  lactate,  and plasma glucose were 
not significantly different between the patients with 
epilepsy and those without epilepsy in either age group.  
The CSF glucose concentration (p = 0.0477) and CSF/
plasma glucose ratio (p = 0.0416) were lower in patients 
with epilepsy than in those without epilepsy.
PCA. The metabolome analysis using GC-MS/MS 
identified 180 metabolite derivatives in the CSF sam-
ples.  PCA was performed initially to detect intrinsic 
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????? ?　 Comparison of clinical characteristics between epilepsy and non-epilepsy groups
Groups Epilepsy Non-epilepsy p-value
Number 34 30
Age 0y 4m-15y 4m (median,  4y 2m) 0y 4m-16y 7m (median,  11y 11m) 0.137
Sex (female) 16 (47%) 15 (50%) 0.814
Age group 0-5 years
　Number 22 13
　Age 0y 4m-5y 10m (median,  3y 0m) 0y 4m-5y 6m (median,  2y 0m) 0.177
　Sex (female) 10 (45%) 6 (46%) 1
　Antiepileptic drugs
　　VPA 13 (59%) 1 (8%) 0.0039
　　LEV 5 (23%) 0 0.134
　　ZNS 4 (18%) 1 (8%) 0.630
　　CBZ 4 (18%) 1 (8%) 0.630
　　LTG 2 (9%) 0 0.519
　　PHT 2 (9%) 0 0.519
　　TPM 2 (9%) 0 0.519
　　BZDs 2 (9%) 1 (8%) 1
　　PB 1 (5%) 0 1
　　ESM 1 (5%) 0 1
　CSF protein (mg/dL) 11-47 (median,  17) 10-32 (median,  18) 0.644
　CSF lactate (mg/dL) 9.9-19.4 (13.5) 11.1-17.4 (12.5) 0.838
　CSF glucose (mg/dL) 43-65 (51.5) 44-59 (51) 0.959
　Plasma glucose (mg/dL) 72-108 (88) 65-103 (86) 0.918
　CSF/plasma glucose 0.46-0.70 (0.59) 0.52-0.68 (0.59) 0.785
Age group 6-17 years
　Number 12 17
　Age 6y 6m-15y 4m (median,  10y 4m) 10y 4m-16y 7m (median,  13y 2m) 0.066
　Sex (female) 6 (50%) 9 (53%) 1
　Antiepileptic drugs
　　VPA 5 (42%) 0 0.0067
　　LEV 5 (42%) 0 0.0067
　　ZNS 4 (33%) 0 0.0208
　　BZDs 4 (33%) 0 0.0208
　　CBZ 3 (25%) 0 0.0602
　　ESM 3 (25%) 0 0.0602
　　LTG 2 (17%) 0 0.163
　　TPM 2 (17%) 0 0.163
　　STM 2 (17%) 0 0.163
　　RFN 1 (8%) 0 0.414
　　PB 1 (8%) 0 0.414
　　PHT 1 (8%) 0 0.414
　CSF protein (mg/dL) 18-63 (25) 12-65 (27) 0.673
　CSF lactate (mg/dL) 8.9-15.8 (12.9) 10.0-15.7 (13.2) 0.965
　CSF glucose (mg/dL) 45-64 (51.5) 50-70 (58) 0.0477
　Plasma glucose (mg/dL) 80-115 (91.5) 87-110 (91) 0.328
　CSF/plasma glucose 0.52-0.63 (0.57) 0.54-0.69 (0.60) 0.0416
p-values are derived from Wilcoxonʼs test,  Chi-square test,  and Fisherʼs exact test.
BZDs,  benzodiazepines; CBZ,  carbamazepine; CSF,  cerebrospinal ﬂuid; ESM,  ethosuximide; LEV,  levetiracetam; LTG,  lamotrigine; PB,  phenobarbital; PHT,  
phenytoin; RFN,  ruﬁnamide; STM,  sulthiame; TPM,  topiramate; VPA,  valproic acid; ZNS,  zonisamide.
data clustering and outliers (Fig. 1).  The PCA score 
plots did not show definite outliers in either age group;  
therefore,  we included the data from all patients for 
subsequent analysis.  There was no clear separation 
between epilepsy and non-epilepsy in either age group,  
suggesting that only a few metabolites had different 
concentrations in the epilepsy and non-epilepsy groups.
Effect of epilepsy on metabolites. Multiple regres-
sion analysis incorporating epilepsy (vs. non-epilepsy,  
categorical variable) and individual AEDs (categorical 
variables,  only AEDs that were significantly different 
between the epilepsy and non-epilepsy groups in Table 
2) as independent variables was performed to investi-
gate the effect of these variables on individual metabo-
lite concentrations (Table 3).  In patients aged 0-5 years,  
there were 3 metabolites with q-values < 0.05 associated 
with epilepsy: 2-ketoglutaric acid (lower in epilepsy),  
pyridoxamine (higher in epilepsy),  and tyrosine (higher 
in epilepsy).  In patients aged 6-17 years,  1,5-anhydro-
glucitol (1,5-AG) showed a significant difference (lower 
in epilepsy).
Effect of AEDs on metabolites. The multiple 
regression analysis also demonstrated which metabo-
lites were affected by AEDs (Table 3).  In patients aged 
0-5 years,  VPA was associated with elevated concentra-
tions of 2-propyl-5-hydroxypentanoic acid.  In patients 
aged 6-17 years,  VPA was associated with elevated 
concentrations of 2-aminobutyric acid,  2-ketoiso-
caproic acid,  2-propyl-5-hydroxypentanoic acid,  
4-hydroxyproline,  acetylglycine,  methionine,  
N-acetylserine,  and serine.  LEV and ZNS were associ-
ated with reduced and elevated concentrations of 1,5-
AG,  respectively.
Relationship between glucose and 1,5-AG.
Because the CSF concentrations of 1,5-AG as measured 
by GC-MS/MS and the CSF concentrations of glucose as 
measured by routine laboratory tests were different 
between the epilepsy and non-epilepsy patients in the 
age group of 6-17 years,  we performed a correlation 
analysis between the concentrations of these metabo-
lites and between the CSF 1,5-AG concentration and 
CSF/plasma glucose ratio.  There were no significant 
correlations between the 1,5-AG and CSF glucose con-
centrations (ρ = −0.0235,  p = 0.904) or between the CSF 
1,5-AG concentration and CSF/plasma glucose ratio 
(ρ = 0.0473,  p = 0.808).
Discussion
We conducted a study of GC-MS/MS-based metab-
olomics using CSF samples from pediatric patients with 
and without epilepsy.  We demonstrated that GC-MS/
MS analysis of the CSF samples was able to detect 180 
metabolite derivatives.
In patients aged 0-5 years,  there were 3 metabolites 
with significant differences in concentration between 
patients with epilepsy and those without epilepsy:  
2-ketoglutaric acid,  pyridoxamine,  and tyrosine.  
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???? ?　 Principal component analysis (PCA) of metabolome data.  Score plots of PCA (ﬁrst and second principal components) with 99% 
conﬁdence ellipses in A) the age group 0-5 years and B) the age group 6-17 years.  There were no outliers.  No deﬁnite separation between 
the epilepsy and non-epilepsy groups could be established.
Pyridoxamine concentrations were higher in epilepsy 
patients than in non-epilepsy patients.  The elevated 
pyridoxamine levels may have been due to reduced con-
version from pyridoxamine to pyridoxal-5’-phosphate 
(PLP) via 2 enzymatic reactions catalyzed by pyridoxal 
kinase and pyridox(am)ine phosphate oxidase (PNPO).  
An extreme example of a condition in which this path-
way is affected is PNPO deficiency,  in which low CSF 
and plasma PLP and elevated plasma pyridoxamine 
concentrations have been reported [6 , 7].  PLP is essen-
tial for GABA synthesis.  In a previous study,  we 
reported lower CSF PLP concentrations in epilepsy 
patients than in non-epilepsy patients [8].  Collectively,  
these findings suggest that vitamin B6 metabolism is 
altered in epilepsy (Fig. 2).
In the tricarboxylic acid cycle,  2-ketoglutaric acid is 
a rate-determining intermediate with a crucial role in 
cellular energy metabolism [9].  2-ketoglutaric acid is 
also produced from glutamate in many transamination 
reactions in the cytosol and mitochondria,  and in oxi-
dative deamination by glutamate dehydrogenase in 
mitochondria [10].  Reduced 2-ketoglutaric acid levels 
suggest impaired energy production in epilepsy and may 
in part be associated with altered vitamin B6 metabo-
lism,  because many aminotransferases are PLP-
dependent (Fig. 2).  Tyrosine is a conditionally essential 
amino acid,  particularly in young children,  and it is 
involved in dopamine synthesis.  Tyrosine is degraded 
to 4-hydroxyphenylpyruvate by tyrosine aminotrans-
ferase,  which is a PLP-dependent enzyme that uses 
tyrosine and 2-ketoglutaric acid as substrates.  
Congenital deficiency of this enzyme is known to cause 
tyrosinemia type II.  In a previous study,  we demon-
strated that PLP administration is associated with a 
reduced concentration of tyrosine [11].  Reduction of 
PLP and 2-ketoglutaric acid together counteracts this 
enzymatic reaction and leads to elevation of tyrosine 
(Fig. 2).
In patients aged 6-17 years,  1,5-AG was signifi-
cantly reduced in patients with epilepsy compared to 
patients without epilepsy.  1,5-AG is a metabolically 
stable sugar alcohol derived mainly from food.  It has a 
high sensitivity to glycemic control.  Serum concentra-
tions of 1,5-AG are reduced by glucosuria,  in which 
glucose in the urine inhibits the reabsorption of 1,5-AG 
in the proximal renal tubules.  Concentrations of 1,5-
AG in CSF and plasma are comparable [12].  The lower 
1,5-AG levels found in patients with epilepsy in the 
present study are difficult to explain,  because there was 
no patient with known glucosuria.  There is also no clear 
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????? ?　 Metabolites associated with epilepsy and antiepileptic drugs
Variables Metabolites p-value q-value
Age group 0-5 years (n=35)
Epilepsy 2-ketoglutaric acid (↓) 0.0003 0.0302
Pyridoxamine (↑) 0.0011 0.0416
Tyrosine (↑) 0.0009 0.0416
VPA 2-propyl-5-hydroxypentanoic acid (↑) ＜0.0001 0.0038
Age group 6-17 years (n=29)
Epilepsy 1,5-anhydroglucitol (↓) 0.0002 0.0292
VPA 2-aminobutyric acid (↑) 0.0025 0.0476
2-ketoisocaproic acid (↑) 0.0007 0.0187
2-propyl-5-hydroxypentanoic acid (↑) 0.0006 0.0187
4-hydroxyproline (↑) 0.0013 0.0285
Acetylglycine (↑) 0.0002 0.0115
Methionine (↑) 0.0029 0.0491
N-acetylserine (↑) 0.0003 0.0115
Serine (↑) 0.0001 0.0115
LEV 1,5-anhydroglucitol (↓) 0.0002 0.0306
ZNS 1,5-anhydroglucitol (↑) ＜0.0001 0.0050
Up and down arrows indicate the eﬀect of the variables on metabolite concentrations.
VPA,  valproic acid; LEV,  levetiracetam; ZNS,  zonisamide.
explanation of the effect of LEV and ZNS on 1,5-AG 
concentrations.  There may be a different mechanism to 
control 1,5-AG concentrations apart from glucose reab-
sorption in the kidney.  For instance,  a positive correla-
tion between serum 1,5-AG and uric acid concentra-
tions has been reported in non-diabetic patients,  and 
1,5-AG and uric acid may share a common transport 
system,  independent of glucose excretion [13].  
Interestingly,  in our study,  patients with epilepsy had 
lower CSF glucose concentrations and CSF/plasma glu-
cose ratios than those without epilepsy,  although these 
were not correlated with CSF 1,5-AG concentrations.  
This finding may be related to the cerebral glucose 
hypometabolism observed by interictal fluorodeoxyglu-
cose positron emission tomography in epilepsy patients 
[14].
VPA was associated with elevated concentrations of 
2-propyl-5-hydroxypentanoic acid,  which is a metabo-
lite of VPA.  VPA is also associated with elevated con-
centrations of various amino acids and related metabo-
lites.  In a previous study,  we reported an association 
between VPA administration and elevated serine and 
methionine [11].  VPA has been reported to impair 
methionine metabolism by inhibiting methionine ade-
nosyltransferase,  which synthesizes S-adenosyl-
methionine from methionine [15].  In our study,  VPA 
was also associated with elevated levels of glycine,  ser-
ine,  and threonine metabolites: serine,  N-acetylserine,  
acetylglycine,  and 2-aminobutyric acid.  2-aminobu-
tyric acid is also associated with methionine metabo-
lism.  N-acetylserine and acetylglycine are derived from 
the degradation of N-terminal acetylated proteins and 
are converted to serine and glycine,  respectively,  by 
aminoacylase 1.  Elevated serine may contribute to ele-
vation of N-acetylserine through negative feedback on 
this enzyme.  The elevation of 2-ketoisocaproic acid,  an 
intermediate metabolite of leucine degradation,  can be 
explained by inhibition of branched-chain amino acid 
catabolism by VPA [16].  Elevation of 4-hydroxyproline 
is a marker of increased collagen turnover.  The func-
tion of collagen in the central nervous system has 
recently been expanded—collagen is no longer consid-
ered a merely structural component,  but rather a 
bio-active molecule playing a dynamic role within the 
central nervous system [17].  The role of VPA in colla-
gen turnover remains to be elucidated.
This study is limited by the small sample size,  and 
thus our results will require further investigation before 
conclusions can be drawn.  We could not find metabo-
lites associated with epilepsy that were common 
between the two age groups.  Although we separated 
patients into two age groups to reduce the effect of age 
on metabolites,  larger samples with fewer confounders 
(e.g.,  variability of age,  medications,  and comorbidi-
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???? ?　 Metabolic links between pyridoxamine,  tyrosine,  and 2-ketoglutaric acid.  Elevated pyridoxamine may be due to reduced produc-
tion of PLP from pyridoxamine via PDXK and PNPO.  This leads to reduced generation of 2-ketoglutamic acid from glutamate and reduced 
degradation of tyrosine,  because these reactions are catalyzed by PLP-dependent enzymes.  PLP is also an essential cofactor for GABA 
biosynthesis in the central nervous system by GAD.  GAD,  glutamate decarboxylase; GABA,  gamma-aminobutyric acid; PDXK,  pyridoxal 
kinase; PLP,  pyridoxal-5ʼ-phosphate; PNPO,  pyridox(am)ine phosphate oxidase.
ties) are required to obtain more reliable results.  
Finally,  the metabolomic findings should be confirmed 
by quantitative assays optimized for individual metabo-
lites.
In conclusion,  metabolome analysis of CSF samples 
using GC-MS/MS detected 180 metabolites.  In the age 
group of 0-5 years,  epilepsy patients had reduced 
2-ketoglutaric acid and elevated pyridoxamine and tyro-
sine concentrations,  compared with those without epi-
lepsy.  These three metabolites were deemed to be asso-
ciated with alterations in vitamin B6 metabolism.  In the 
age group of 6-17 years,  epilepsy patients had reduced 
concentrations of 1,5-AG,  compared with those with-
out epilepsy.  The biological significance of these find-
ings remains to be explained.  VPA had an influence on 
various amino acids and related metabolites involved in 
the metabolism of serine,  methionine,  and leucine.
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